Evidence map›Paper›PMID 25395928›Full record

ReviewPostepy dermatologii i alergologii2014

Chromoblastomycosis.

Paweł M Krzyściak, Małgorzata Pindycka-Piaszczyńska, Michał Piaszczyński

Open access · goldAbstract readReview
In one paragraph

Review in Postepy dermatologii i alergologii, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. American journal of ophthalmology case reports · 2023
    Article
  7. Biofilm Formation by Chromoblastomycosis FungiJournal of fungi (Basel, Switzerland) · 2022
    Article
  8. Article
  9. Article
  10. Retinoids in Fungal Infections: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  11. Article
  12. Chromoblastomycosis Caused byJournal of fungi (Basel, Switzerland) · 2021
    Article
  13. Review
  14. Subcutaneous Mycoses in Travelers.Current tropical medicine reports · 2020
    Article
  15. Antimicrobial agents and chemotherapy · 2020
    Article
  16. Review
  17. Article
  18. Answer to February 2020 Photo Quiz.Journal of clinical microbiology · 2020
    Article
  19. Frontiers in immunology · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Paweł M KrzyściakDepartment of Mycology, Chair of Microbiology, Jagiellonian University Medical College, Krakow, Poland. Head of Department: Paweł M. Krzyściak MD, PhD.
Małgorzata Pindycka-PiaszczyńskaChair and Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Barbara Rogala MD, PhD.
Michał PiaszczyńskiDepartment of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Lech Cierpka MD, PhD.
Medical University of Silesia · PLJagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromoblastomycosis is a chronic fungal infection of the skin and subcutaneous tissue. The infection usually results from a traumatic injury and inoculation of microorganism from a specific group of dematiaceous fungi (usually Fonsecaea pedrosoi, Phialophora verrucosa, Cladophialophora carrionii). In the tissues fungi produce characteristic sclerotic cells or muriform cells. Dermal lesions can range from small nodules to large papillary-like eruptions. The disease has been described worldwide but the prevalence is higher in rural populations in countries with a tropical or subtropical climate, such as Madagascar in Africa and Brazil in South America. Diagnostic techniques are based on direct examination, culture and histopathology. Despite a variety of treatment modalities, which include long courses of antifungals, surgical excision and destructive physical therapies, the disease remains one of the most difficult deep mycotic infections to eradicate.

Indexed as

diagnosisepidemiologyFonsecaea pedrosoimycosestreatment

Identifiers

PMID25395928
PMCPMC4221348
OpenAlexW2594044485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.